688399.SH
Jiangsu Bioperfectus Technologies Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 27.85
−2.76%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 326.0M | 339.0M | 349.6M | 403.2M | 5.5B |
| Cost of Revenue | 118.8M | 124.9M | 132.0M | 145.5M | 2.2B |
| Gross Profit | 207.2M | 214.1M | 217.7M | 257.7M | 3.4B |
| Operating Expenses | |||||
| R&D Expense | 74.5M | 78.7M | 100.9M | 135.5M | 185.8M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 81.6M | 82.5M | 82.6M | 177.2M | 297.2M |
| Selling & Marketing Expense | 123.0M | 128.6M | 131.3M | 200.2M | 422.5M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 293.3M | 299.2M | 288.5M | 473.4M | 903.7M |
| Cost and Expenses | 412.1M | 424.1M | 420.5M | 618.9M | 3.1B |
| Operating Income (EBIT) | (18.7M) | (30.0M) | 8.8M | (365.1M) | 2.1B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (19.4M) | (32.1M) | 4.2M | (375.7M) | 2.1B |
| Income Tax Expense | 13.4M | 9.0M | 6.2M | (1.9M) | 310.8M |
| Bottom Line | |||||
| Net Income | (32.8M) | (41.1M) | (2.0M) | (373.8M) | 1.8B |
| Earnings from Cont. Ops | (32.8M) | (41.1M) | (2.0M) | (373.8M) | 1.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.8M) | (41.1M) | (2.0M) | (373.8M) | 1.8B |
| Per Share | |||||
| Basic EPS | (CN¥0.40) | (CN¥0.49) | (CN¥0.02) | (CN¥6.38) | CN¥31.18 |
| Diluted EPS | (CN¥0.40) | (CN¥0.49) | (CN¥0.02) | (CN¥6.38) | CN¥31.18 |
| Revenue Per Share | CN¥3.86 | CN¥4.04 | CN¥3.49 | CN¥6.88 | CN¥94.41 |
| Shares | |||||
| Basic Shares Outstanding | 84.5M | 83.8M | 100.1M | 58.6M | 58.6M |
| Diluted Shares Outstanding | 84.5M | 83.8M | 100.1M | 58.6M | 58.6M |
| Profitability Metrics | |||||
| EBITDA | — | 48.8M | 80.4M | (264.4M) | 2.3B |
| D&A | — | 78.8M | 71.6M | 100.6M | 100.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026